Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (children) meta-analysis

PREVENT-19 adolescents unpublished
  NCT04611802		 RCTNuvaxovid (NVX-CoV2373) NovavaxplaceboCOVID-19 prophylaxis (children)NA
-/- suggested
  • suggested 82 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
Trial demonstrated 82% clinical efficacy against Delta variant. from press release (https://ir.novavax.com/2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons